InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
0
T+90 hit rate
33%
T+90 mean return
+5.5%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by MANHARD KIMBERLY, Directeur Exécutif. Insider active across 3 companies, notably Heron Therapeutics, INC.. Cumulatively, 15 filings have been published. Split: 1 buy · 0 sell. Total volume traded: €126k. History available since 30 April 2021. The latest transaction was filed on 28 August 2024 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations15 total
10,000 shares@ US$13.98100.0% of flowCommon StockSEC:0002007919-24-000042:0
Ideal exit: 25 May 2025 (T+270)
1,250 sharesCommon StockSEC:0001209191-23-024497:0
1,655 shares@ US$3.2725100.0% of flowCommon StockSEC:0001209191-23-003560:0
1,250 sharesCommon StockSEC:0001209191-22-053827:0
1,250 sharesCommon StockSEC:0001209191-22-042259:0
1,504 shares@ US$3.8420.0022% mcap13.6% of flowCommon StockSEC:0001209191-22-027232:0
1,250 sharesCommon StockSEC:0001209191-22-024519:0
1,250 sharesCommon StockSEC:0001209191-22-003358
1,250 sharesCommon StockSEC:0001209191-22-003358:0
1,250 sharesCommon StockSEC:0001209191-21-060547:0
1,250 sharesCommon StockSEC:0001209191-21-060547
1,250 sharesCommon StockSEC:0001209191-21-046786
1,250 sharesCommon StockSEC:0001209191-21-046786:0
1,529 shares@ US$13.89750.0072% mcap43.2% of flowCommon StockSEC:0001209191-21-030014:0
1,529 shares@ US$13.897543.2% of flowCommon StockSEC:0001209191-21-030014
15 of 15 declarations
About MANHARD KIMBERLY
Kimberly Manhard is Executive Vice President, Drug Development at Heron Therapeutics, Inc., a biopharmaceutical company. She oversees drug development, playing a key role in innovation and research within the company.
